Serum REG3alpha and C-Reactive Protein Levels in Crohn's Disease Patients Undergoing Immunoablation and Autologous Hemopoetic Stem Cell Transplantation in the ASTIC Trial by Greuter, Thomas et al.
E-Mail karger@karger.com
 Original Paper 
 Digestion 2015;92:83–89 
 DOI: 10.1159/000437300 
 Serum REG3alpha and C-Reactive Protein 
Levels in Crohn’s Disease Patients Undergoing 
Immunoablation and Autologous Hemopoetic 
Stem Cell Transplantation in the ASTIC Trial 
 Thomas Greuter  a    Silvia Lang  a    Ernst Holler  b    Christopher J. Hawkey  c    
Gerhard Rogler  a    Luc Biedermann  a    ASTIC trial group  
 a   Division of Gastroenterology and Hepatology, University Hospital Zurich,  Zurich , Switzerland;  b   Department of 
Hematology/Oncology, University Medical Center Regensburg,  Regensburg , Germany;  c   Nottingham Digestive 
Diseases Centre, University of Nottingham,  Nottingham , UK
 
22.6–258.3). No significant elevation of REG3α was found 
among patients with active disease compared to those in 
remission (106.3 vs. 91.4). Patients with moderate to severe 
endoscopic disease activity showed substantially, although 
not significantly elevated REG3α levels compared to those 
in remission (95.4 vs. 52.4, p = 0.052). Baseline serum REG3α 
levels of patients without clinical or endoscopic remission 
1 year after HSCT were not elevated compared to those in 
remission (63.1 vs. 66.9, and 68.4 vs. 59.2, respectively). In 
contrast, CRP was significantly elevated in patients with ac-
tive disease compared to patients in remission (14.1 vs. 
6.0  mg/dl, p  = 0.032). In addition, CRP was elevated, al-
though not significantly, in patients with severe endoscop-
ic disease compared to those in endoscopic remission (18.7 
vs. 4.1, p = 0.062). Furthermore, baseline CRP was reduced 
in patients with clinical and endoscopic remission after 
HSCT compared to those without remission, although not 
significantly (8.8 vs. 21.4, n.s. and 8.1 vs. 12.4, n.s.).  Conclu-
sion: Given the divergent findings compared to GvHD, we 
conclude that serum REG3α is not an accurate diagnostic 
and pre dictive biomarker in CD patients undergoing HSCT. 
In contrast, CRP is a valuable biomarker in order to differen-
tiate active disease from remission. However, CRP does not 
seem to be of prognostic value for HSCT outcome. 
 © 2015 S. Karger AG, Basel 
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 Abstract 
 Background: REG3α has been recently shown to be a high-
ly accurate biomarker for graft-versus-host-disease (GvHD). 
Given the unmet need of such biomarkers in Crohn’s dis-
ease (CD) and the similarities between CD and GvHD, we 
aimed at investigating the role of serum REG3α as a diag-
nostic and prognostic biomarker in CD patients undergoing 
autologous hemopoetic stem cell transplantation (HSCT) in 
the multicenter Autologous Stem Cell Transplantation In-
ternational Crohn’s Disease (ASTIC) trial and to compare it 
to C-reactive protein (CRP).  Methods: Stored serum samples 
from the ASTIC trial were analyzed using a commercially 
available human PAP1 ELISA-kit to measure REG3α levels. 
CRP was available from prior analysis in the ASTIC trial. 
These levels were correlated with clinical and endoscopic 
disease activity as well as overall clinical and endoscopic 
outcome 1 year after autologous HSCT.  Results: One hun-
dred thirty two serum samples were available for analysis. 
The mean concentration of REG3α was 101.8 ng/ml (95% CI 
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 Introduction 
 The 3 REG3 genes alpha, beta, and gamma all seem to 
be involved in the growth of cells and tissues in the gas-
trointestinal tract  [1] . The human equivalent of REG3α is 
HIP/PAP  [2, 3] and is located on chromosome 2  [1] . It 
encodes C-type lectine-like proteins, which are secreted 
into the gut lumen by Paneth cells  [4, 5] . Due to their an-
timicrobial activity, REG3α protein seems to support the 
epithelial barrier function in the gastrointestinal tract  [5] . 
Interestingly, gastrointestinal inflammation leads to an 
increased secretion of REG3α via increased interleu-
kin-22 (IL-22)  [6] . However, commensal microflora is re-
quired for the increase in IL-22 production  [7] . Hence, 
IL-22 has been shown to be low in germ-free mice. IL-22 
stimulates the production of S100a and REG3α (both in-
volved in antimicrobial defense of epithelial cells) via its 
IL-22 receptor  [6] . Given the fact that the IL-22 receptor 
is exclusively expressed on intestinal epithelial cells, it is 
considered to be an important factor in the communica-
tion between immune and intestinal epithelial cells  [8] . 
Moreover, the so-called IL-22/REG3-axis has been shown 
to be the first known molecular pathway, enlightening 
how immune cells instruct and communicate with epi-
thelial cells  [7] .
 Graft-versus-host-disease (GvHD) shares many simi-
larities (histological features and genetic risk factors) with 
Crohn’s disease (CD)  [9] . Mucosal damage in GvHD in-
creases REG3α, which can transverse consecutively into 
systemic circulation. Recently, REG3α has been shown to 
be a highly accurate diagnostic and prognostic biomarker 
with remarkable specificity for lower gastrointestinal 
GvHD after allogeneic hemopoetic stem cell transplanta-
tion (HSCT), allowing better risk stratification of patients 
and the prediction of non-relapse mortality  [10] . Serum 
REG3α seems to be a surrogate marker for the cumulative 
area of damage. Hence, it seems to be a direct indicator of 
intestinal mucosal damage rather than just activated sys-
temic inflammatory response like C-reactive protein 
(CRP) or fecal calprotectin  [10] . In a previous investiga-
tion in patients undergoing allogeneic HSCT, the trans-
plant-related mortality revealed to increase stepwise in 
donor/recipient pairs with NOD2/CARD15 mutations 
either only in the donor or only in the recipient or in both 
compared to pairs without mutated single nuclear poly-
morphisms  [11, 12] . This is of particular interest given the 
fact, that NOD2 variant patients have significantly in-
creased REG3α levels compared to NOD2 wild type pa-
tients. Hence, REG3α may also have a prognostic value in 
allogeneic HSCT without the complication of GvHD.
 While knowledge about the role of REG3α in CD 
pathogenesis is relatively new, CRP has been studied for 
years. CRP has been shown to be associated with disease 
activity in CD and increased CRP levels are associated 
with higher response rates to anti-TNF treatments  [13] . 
However, CRP can be elevated in virtually all inflamma-
tory disorders and therefore, it is very unspecific for CD 
alone. In addition, in some individuals, CRP may not be 
elevated due to genetic variants  [14, 15] . And – in contrast 
to REG3α – specificity and sensitivity for GvHD have 
been shown to be very low  [16] . Despite these limitations, 
CRP remains the best, but imperfect serum biomarker for 
disease activity in CD. However, accurate non-invasive 
biomarkers for CD activity and mucosal damage are still 
an unmet need. Particularly, this seems to be true in the 
context of recent findings, suggesting a low correlation 
between symptom severity and endoscopic disease 
 activity  [17] .
 Autologous HSCT has been shown to be an effective 
treatment option in a variety of severe autoimmune dis-
eases refractory to conventional therapy  [18] . The Au-
tologous Stem Cell Transplantation International Crohn’s 
Disease (ASTIC) trial is the only randomized controlled 
trial investigating the role of autologous HSCT in CD. 
The trial was conducted as a multicenter study in 10 dif-
ferent countries and revealed a substantial reduction in 
symptomatic and endoscopic activities in severe CD after 
autologous HSCT compared to mobilization alone  [19–
21] . In this study, we aimed at investigating the role of the 
novel promising biomarker REG3α in order to assess its 
diagnostic and prognostic potential in CD patients un-
dergoing immunoablation and autologous HSCT in the 
multicenter ASTIC trial and to compare this role to CRP, 
the so far best, but imperfect CD serum marker  [13] .
 Methods 
 Patients and Samples 
 During the ASTIC trial, heparinized serum samples were col-
lected prospectively and stored at the University of Nottingham at 
–80   °   C. Sample processing and storage were performed as previ-
ously described  [22] . Samples were shipped from Nottingham to 
Zurich and were received frozen on dry ice. No sample was thawed 
more than once before analysis. Serum samples were analyzed us-
ing a commercially available human PAP1 ELISA-kit to measure 
serum REG3α levels. Clinical, laboratory (including CRP), and en-
doscopic data were available from the ASTIC trial.
 ASTIC Trial 
 The ASTIC trial, a randomized controlled, multicenter study in 
10 different countries, was conducted from July 2007 to May 2013 
as to investigate the role of autologous HSCT in severe CD. The 
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study was approved by the EBMT/EULAR Working Party Autoim-
mune Diseases, ECCO Scientific Committee and by the relevant 
Competent Authorities, Ethical Committees and Institutional Re-
view Boards. Forty-five patients were enrolled. Inclusion criteria 
were (1) age between 18 and 50 years, (2) confirmed diagnosis of 
CD based on typical radiological appearances and/or typical histol-
ogy, (3) active disease at registration defined as CDAI >250 and >2 
of the following: raised CRP, endoscopic evidence of active disease 
confirmed on histology, clear evidence of small bowel CD on small 
bowel barium study, (4) unsatisfactory course despite 3 immuno-
suppressive agents, (5) impaired function and quality of life, (6) 
current problems unsuitable for surgery, (7) informed consent. Pa-
tients were excluded for (1) pregnancy, (2) concomitant severe dis-
ease such as renal failure, congestive heart failure, psychiatric dis-
orders, (3) diarrhea due to short small or large bowel, (4) infection 
or risk thereof, (5) significant malnutrition, (6) previous poor com-
pliance. All patients received mobilization treatment (intravenous 
cyclophosphamide over 2 days, then filgrastim daily) prior to ran-
domization into either immediate (1  month) or delayed (13 
months) immunoablation and autologous HSCT. All patients were 
followed up by 6-weekly assessments for 52 weeks after transplan-
tation. At every follow-up visit, clinical disease activity was mea-
sured by CDAI  [23] and HBI  [24] . At baseline, endoscopic disease 
activity was assessed by upper endoscopy and ileocolonoscopy us-
ing CDEIS  [25] . Further assessment tools consisted of adverse 
events evaluation, quality-of-life questionnaires, evaluation of 
medication use, and laboratory parameters (CRP, platelet count).
 ELISAs 
 REG3α ELISA kits from MBL International Corporation 
 (Ab-Match Assembly Human PAP1 kit, catatolog number 5323, 
and Ab-Match Universal kit, catalog number 5310, Woburn, 
Mass., USA) were used. All measurements were performed ac-
cording to the manufacturer’s protocol. All samples were diluted 
1: 10 according to the protocol and as recommended, all calibra-
tors, controls, and patient samples were analyzed in duplicate. One 
standard curve per assay was made. Absorbance of each well was 
read at test wavelength of 450 and 620 nm with the multi detection 
microplate reader Synergy 2 (Biotek Instruments, Winooski, Vt., 
USA). Results were calculated with Gen 5 version 1.11 (Biotek In-
struments). Only values within the range of the standard curve 
were used for further analysis. If duplicates varied more than 16%, 
ELISA was repeated for this sample.
 Statistical Analysis 
 Serum REG3α and CRP levels at any timepoint during the 
 ASTIC trial were correlated with clinical (CDAI) and endoscopic 
disease activity (CDEIS). In addition, baseline serum REG3α and 
CRP were correlated with the overall outcome 1 year after autolo-
gous HSCT in patients randomized to the immediate transplanta-
tion group (see section ASTIC trial), which was assessed by chang-
es in CDAI and CDEIS, and by clinical (CDAI  ≤ 150) or endoscop-
ic remission (CDEIS <4), respectively, in order to evaluate its 
prognostic potential. For statistical analysis, the IBM Software 
SPSS Statistics version 22.0.0 (2013 SPSS Science, Inc., Chicago, 
Ill., USA) was used. The Mann–Whitney U test was used for com-
parison between different subgroups as data was ordinary or con-
tinuous with a non-normal distribution. To investigate the prog-
nostic potential of REG3α and CRP, baseline serum levels in pa-
tients with clinical and/or endoscopic remission were compared 
with serum levels in patients with no remission by using the 
Mann–Whitney U test. A 2-sided p value of <0.05 was considered 
statistically significant.
 Results 
 Study Population 
 As of January 2014, 132 serum samples were available 
from 35 of the 45 ASTIC trial participants. Twenty patients 
(58.8%) were female and the mean age at mobilization was 
32.0 years (95% CI 20.9–45.7). All patients (100.0%) had 
been previously treated with at least one TNF-blocker and 
9 (27.3%) were still treated with an anti-TNF at registration. 
Five patients (15.2%) were on systemic steroids at study en-
rolment. By inclusion criteria, all patients had active disease 
at pre-registration. At baseline evaluation (within several 
weeks after registration) mean CDAI was 338.3 (95% CI 
115.3–512.4), only 3 patients reported to have a CDAI of 
 ≤ 150 at baseline. The mean endoscopic disease activity at 
baseline (CDEIS) was 1.9 (95% CI 0.0–10.0) in upper en-
doscopy and 12.9 (95% CI 0.0–26.0) in ileocolonoscopy. 
Baseline CRP was elevated with a mean of 20.0 mg/dl (95% 
CI 0.5–109.0). Demographic data is summarized in  table 1 .
 Serum REG3α Levels at Baseline and during the 
ASTIC Trial 
 The mean concentration of serum REG3α at baseline 
was 85.6 ng/ml (n = 28, 95% CI 21.7–220.7). The mean 
serum level of REG3α at any timepoint was 101.8 ng/ml 
(n = 132, 95% CI 22.6–258.3). Changes in serum REG3α 
Table 1.  Baseline demographic data
n = 34* (95% CI) %
Sex, female 20 58.8
Mean age, years 32.0 (20.9–45.7)
Ethnicity: Caucasian 34 100.0
Allergy/atopic diseases 18 52.9
Positive family history for IBD 5 14.7
Current smoker 7 20.6
Past smoker 12 35.3
Ileostomy 9 26.5
Colectomy 13 38.2
Ileal resection 10 29.4
Operations 2.4 (0.0–6.0)
Mean CDAI at baseline 338.3 (115.3–512.4)
Mean CDEIS at baseline 12.9 (0.0–26.0)
Mean CRP at baseline, mg/dl 20.0 (0.5–109.0)
Mean REG3α, ng/ml 85.6 (21.7–220.7)
 * Data of one patient was missing.
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levels during the ASTIC trial are shown in online supple-
mentary figure 1 (for all online suppl. material, see www.
karger.com/doi/10.1159/000437300). Both baseline and 
overall serum REG3α levels were elevated compared to 
those of the normal population (n = 80, reference 95% CI 
10.6–56.7 ng/ml, according to manufacturer’s protocol).
 Diagnostic Value of Serum REG3α Levels in Severe 
CD Patients 
 CDAI at different timepoints during the ASTIC trial 
was correlated with serum REG3α levels. Therefore, we 
compared REG3α levels of patients with a CDAI of  ≤ 150, 
indicating clinical remission with serum levels of patients 
with a CDAI of  ≥ 151, indicating active disease. A total of 
26 CDAI of  ≤ 150 contrasted a number of 74 with a CDAI 
of  ≥ 151. No significant elevation of serum REG3α levels 
was found between these 2 groups (91.4 vs. 106.3). In con-
trast, CDEIS was relevantly elevated at timepoints with ac-
tive disease compared to timepoints with clinical remis-
sion, although not significantly (10.7 vs. 5.9, p = 0.075;  ta-
ble  2 ). Consecutively, endoscopic disease activity at 
different timepoints during the ASTIC trial was correlated 
with serum REG3α concentration. REG3α levels at time-
points with a CDEIS of more than 9, indicating moderate 
to severe endoscopic disease activity, were substantially al-
though not significantly elevated compared to timepoints 
in endoscopic remission, defined as a CDEIS of less than 3 
(95.4 vs. 52.4, p = 0.052). Likewise, serum from timepoints 
with mild endoscopic disease activity (CDEIS 3–9) did not 
show any significant elevation or reduction compared to 
endoscopic remission or severe endoscopic activity (110.2 
vs. 52.4, and 110.2 vs. 95.4, respectively;  fig. 1 ).
 Prognostic Value of Serum REG3α Levels in CD 
Patients Undergoing Immunoablation and 
Autologous HSCT 
 To evaluate the prognostic value of serum REG3α con-
centration in the ASTIC trial, baseline levels of patients 
without clinical (CDAI  ≥ 151, n = 8) or endoscopic remis-
sion (CDEIS  ≥ 4, n = 5) 1 year after autologous HSCT were 
compared with levels of patients in remission (clinical re-
mission n = 6; endoscopic remission, n = 6). REG3α was 
analyzed only in samples from patients randomized to the 
early intervention group. Analysis did not show elevated 
serum levels in patients without future remission com-
pared to patients with future remission after autologous 
HSCT (clinical remission 63.1 vs. 66.9, and endoscopic 
remission 68.4 vs. 59.2, respectively). Changes in CDAI 
or CDEIS after autologous HSCT did not show any cor-
relation with REG3α levels at baseline assessment ( fig. 2 ).
Table 2.  Mean REG3α levels and key clinical parameters according to low and elevated CDAI group
CDAI 
group
REG3α, mean, ng/ml 
(95% CI)
CDAI, mean
(95% CI)
CRP, mean, 
mg/dl (95% CI)
CDEIS, mean
(95% CI)
≤150 (n = 26) 91.4 (16.7–243.1)
(n = 26)
79.7 (15.6–144.7)
(n = 26)
6.0 (0.1–21.0)
(n = 21)
5.9 (0.0–22.0)
(n = 11)
≥151 (n = 74) 106.3 (23.4–351.5)
(n = 74)
297.2 (162.3–507.6)
(n = 74)
14.1 (0.2–51.0)
(n = 49)
10.7 (0.0–26.0)
(n = 42)
p value 0.289 <0.001 0.032 0.075
0
20
40
60
80
100
120
140
CDEIS <3 CDEIS 3–9 CDEIS >9
??
?
??
???
??
?
??
*
* p = 0.052
???????????????
????? ?????? ??????
 Fig. 1. Mean REG3α levels according to CDEIS group. 
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 Diagnostic and Prognostic Value of CRP in CD 
Patients Undergoing Immunoablation and 
Autologous HSCT 
 Baseline CRP and CRP values throughout the ASTIC 
trial are shown in  table 3 and in online supplementary 
figure 2, respectively. Both values were found to be el-
evated. In contrast to REG3α, CRP was elevated in pa-
tients with active disease (CDAI  ≥ 151) compared to 
those in clinical remission (CDAI  ≤ 150). Difference 
was statistically significant (14.1 vs. 6.0, p = 0.032). In 
order to assess CRP’s potential to differentiate severe 
endoscopic disease activity from milder forms, CRP 
levels of different CDEIS groups were compared, which 
are shown in  table 3 . Patients with a CDEIS of more 
than 9 showed a relevantly elevated CRP compared to 
those with a CDEIS of less than 3 (18.7 vs. 4.1). How-
ever, the difference was not statistically significant (p = 
0.062). Contrary to REG3α, baseline CRP was mark-
edly reduced in patients with clinical or endoscopic re-
mission 1 year after HSCT compared to those without 
remission (8.8 vs. 21.4, and 8.1 vs. 12.4). However, 
these  differences did not reach statistical significance 
 ( table 3 ).
 Discussion 
 REG3α has been shown to be a highly accurate bio-
marker specific for lower GvHD, a disease state harbor-
ing many similarities with CD, through an unbiased, 
in-depth tandem MS-based discovery approach that can 
quantify proteins at low concentrations  [9, 10] . A lead-
ing hypothesis is that the epithelial barrier function in 
the gastrointestinal tract is supported by the antimicro-
bial activity of REG3α, which is secreted by Paneth cells 
into the crypt microenvironment  [5] . In addition, secre-
tion of REG3α is increased by gastrointestinal inflam-
mation via IL-22  [6] . Mucosal damage could be corre-
lated with high serum REG3α levels in GvHD, which 
suggests that breaches in the epithelial barrier caused by 
severe inflammation permit REG3α to traverse into the 
systemic circulation  [10] . Therefore, REG3α is thought 
0
20
40
60
80
100
Clinical Endoscopic
No remission
Remission
n = 8 n = 6 n = 5 n = 6
* p = 0.947 ** p = 0.796
* **
??
??
???
??
??
?
??
???
??
?
??
????????????????????????????? ?????
 Fig. 2. Baseline REG3α levels in patients with and without clinical 
or endoscopic remission. 
Table 3.  Diagnostic and prognostic value of CRP
CRP values Mean, mg/dl (95% CI) p values
Baseline CRP (n = 23) 20.0 (0.5–109.0)
CRP at any timepoint (n = 70) 11.6 (0.1–46.0)
Diagnostic value
CDAI ≤150 (n = 21) 6.0 (0.1–21.0)
CDAI ≥151 (n = 49) 14.1 (0.2–51.0) 0.032
CDEIS <3 (n = 7) 4.1 (0.0–18.0) 0.376 (CDEIS <3 vs. CDEIS 3–9)
CDEIS 3–9 (n = 16) 8.6 (0.0–44.0) 0.267 (CDEIS 3–9 vs. CDEIS >9)
CDEIS >9 (n = 21) 18.7 (0.7–58.0) 0.062 (CDEIS <3 vs. CDEIS >9)
Prognostic value
Clinical remission (n = 6) 8.8 (0.0–22.0)
No clinical remission (n = 9) 21.4 (0.6–125.0) 0.689
Endoscopic remission (n = 10) 8.1 (0.0–25.0)
No endoscopic remission (n = 5) 12.4 (0.9–41.0) 1.000
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to be a powerful indicator of the cumulative intestinal 
mucosal damage rather than just activated inflamma-
tory response, a parameter impossible to measure by in-
dividual tissue biopsies  [10] . Furthermore, baseline se-
rum REG3α levels have been shown to be of high prog-
nostic value regarding the outcome of GvHD therapy 
 [10] . These features imply that REG3α might serve as a 
valuable candidate biomarker in CD. Given the fact, 
that accurate noninvasive biomarkers are still an unmet 
need in CD, this seems to be of clinical interest, in par-
ticular. However, in contrast to the shared similarities 
of GvHD with CD and the suggested surrogacy for in-
testinal mucosal damage – we did not observe any diag-
nostic or prognostic value of serum REG3α levels for 
severe CD in this study. Serum REG3α levels at time-
points with high CDAI scores indicating active disease 
were not elevated compared to timepoints with clinical 
remission. At least, we detected remarkably – although 
not significantly – higher serum REG3α levels in pa-
tients with severe endoscopic disease activity compared 
to those in endoscopic remission. Baseline serum REG3α 
levels of patients without clinical and/or endoscopic re-
mission 1 year after autologous HSCT were not elevated 
compared to patients in remission indicating no prog-
nostic utility of REG3α in the  ASTIC trial. In contrast 
to REG3α, CRP distinctly discriminated between active 
disease and clinical remission based on symptom sever-
ity (assessed by CDAI). In addition, patients with severe 
endoscopic disease activity showed higher CRP levels 
than those in endoscopic remission, although this dif-
ference reached only borderline significance.
 Our findings suggest that REG3α may be a more spe-
cific biomarker for GvHD and thus may be of no value 
for CD. One possible explanation may be the different 
pathophysiology of GvHD compared to CD with intes-
tinal stem cells (ISCs) as principal cellular targets and 
the consecutive lack of mucosal regeneration  [26] . Pan-
eth cells are in close proximity with ISCs, and this leads 
to high concentrations of REG3α in this microenviron-
ment in the presence of an inflammation. Therefore, 
mucosal barrier disruption induced specifically by stem 
cell dropout – as in GvHD – may allow REG3α to tra-
verse into the systemic circulation  [10] . So, different 
patterns of mucosal damage may lead to a different de-
gree of REG3α secretion into the blood stream. Further-
more, highly active disease causing mucosal damage 
may also lead to a breakdown of Paneth cells, which may 
lower their potential to secrete REG3α into the gut lu-
men and consecutively into systemic circulation. In 
contrast, our data supports prior studies evaluating 
CRP’s role as the best, but imperfect serum marker for 
CD activity.
 A limitation of this study certainly is the incomplete 
serum sample set with samples available from only 35 
of the total 45 patients from the ASTIC trial. Also, se-
rum samples of each individual patient were not stored 
from every timepoint throughout the ASTIC trial. This 
may have underpowered the analyses made in this 
study. Differences in CRP levels between patients with 
clinical/endoscopic remission after HSCT and those 
without remission might have reached statistical signif-
icance with a larger study population. The same might 
be true for the assessment of endoscopic disease activ-
ity by CRP and REG3α. Furthermore, our study includ-
ed only selected patients with highly active disease, 
which is reflected by the high proportion of CDAI 
scores of more than 150 throughout the ASTIC trial. 
Based on the explanation of Paneth cell breakdown 
causing lower REG3α secretion given earlier, REG3α 
may have been more discriminative in patients with less 
active disease. In addition, NOD2 mutation status was 
not included in the analysis. NOD2 variant patients 
have been shown to have significantly higher REG3α 
levels as compared to NOD2 wild type patients. In ad-
dition, NOD2/CARD15 mutations are associated with 
higher mortality in patients undergoing allogeneic 
HSCT and have been shown to be an important prog-
nostic factor  [11, 12] . Thus, subgroup analysis in pa-
tients with NOD2 variants would have been of special 
interest. REG3α might be more discriminative in these 
patients.
 In conclusion, we did not observe a correlation be-
tween serum REG3α levels and CD activity except for a 
trend regarding endoscopic disease activity scores. In 
contrast to the findings in GvHD after allogeneic HSCT, 
baseline REG3α did not have any prognostic value for 
clinical and endoscopic outcome 1 year after autologous 
HSCT. Thus, REG3α may be more specific for GvHD 
than previously thought. Given the divergent findings 
compared to GvHD, we conclude that REG3α is not a 
promising diagnostic and predictive biomarker in CD pa-
tients undergoing autologous autologous HSCT. How-
ever, further studies with higher case loads are needed to 
further investigate the diagnostic and prognostic role of 
serum REG3α in CD, also aside from autologous HSCT. 
In contrast to REG3α, CRP as the so far best serum mark-
er in CD seems to be adequate for discrimination be-
tween  active disease and clinical remission. However, 
CRP does not seem to be of prognostic value for HSCT 
outcome.
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